High Free Cash Flow Stocks
AUPH is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
AURINIA PHARMACEUTICALS INC (AUPH) Stock Price & Overview
NASDAQ:AUPH • CA05156V1022
Current stock price
15.39 USD
0 (0%)
Last:
The current stock price of AUPH is 15.39 USD. Today AUPH is down by 0%. In the past month the price decreased by -0.55%. In the past year, price increased by 87.39%.
AUPH Key Statistics
52-Week Range7.285 - 16.88
Current AUPH stock price positioned within its 52-week range.
1-Month Range15.05 - 16.88
Current AUPH stock price positioned within its 1-month range.
- Market Cap
- 2.046B
- P/E
- 19.00
- Fwd P/E
- 19.05
- EPS (TTM)
- 0.81
- Dividend Yield
- N/A
AUPH Stock Performance
Today
0%
1 Week
-4.68%
1 Month
-0.55%
3 Months
+5.88%
Longer-term
6 Months +16.82%
1 Year +87.39%
2 Years +202.26%
3 Years +36.76%
5 Years +15.94%
10 Years +426.88%
AUPH Stock Chart
AUPH Stock Screens
AUPH currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
AUPH is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
Revenue Growth Leaders
AUPH is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
CAN SLIM Stocks
AUPH is part of our CAN SLIM stock list, indicating it is suited for high growth momentum investing and is a technical leader.
High EPS Growth Stocks
AUPH occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.
Minervini Stocks
AUPH is part of our Minervini Stocks list, indicating it shows strong fundamental growth characteristics and technical strength.
Insider Buying Stocks
AUPH is part of our Insider Buying Stocks list, indicating stock insiders are buying the stock.
AUPH Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AUPH. When comparing the yearly performance of all stocks, AUPH is one of the better performing stocks in the market, outperforming 89.2% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AUPH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AUPH. AUPH has an excellent financial health rating, but there are some minor concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AUPH Earnings
On April 30, 2026 AUPH reported an EPS of 0.26 and a revenue of 77.11M. The company beat EPS expectations (17.65% surprise) and beat revenue expectations (1.01% surprise).
Next Earnings DateJul 29, 2026
Last Earnings DateApr 30, 2026
PeriodQ4 / 2025
EPS Reported$0.26
Revenue Reported77.114M
EPS Surprise 17.65%
Revenue Surprise 1.01%
AUPH Forecast & Estimates
13 analysts have analysed AUPH and the average price target is 17.34 USD. This implies a price increase of 12.67% is expected in the next year compared to the current price of 15.39.
For the next year, analysts expect an EPS growth of -0.27% and a revenue growth 16.21% for AUPH
Analysts
Analysts78.46
Price Target17.34 (12.67%)
EPS Next Y-0.27%
Revenue Next Year16.21%
AUPH Index Membership
AUPH is currently included in the following stock indexes tracked on ChartMill.
AUPH Financial Highlights
Over the last trailing twelve months AUPH reported a non-GAAP Earnings per Share(EPS) of 0.81. The EPS increased by 800% compared to the year before.
Income Statements
Revenue(TTM)283.06M
Net Income(TTM)287.20M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 101.47% | ||
| ROA | 38.21% | ||
| ROE | 49.4% | ||
| Debt/Equity | 0.09 |
Chartmill High Growth Momentum
EPS Q2Q%2500%
Sales Q2Q%28.81%
EPS 1Y (TTM)800%
Revenue 1Y (TTM)20.38%
AUPH Ownership
Ownership
Inst Owners55.55%
Shares132.97M
Float123.75M
Ins Owners1.24%
Short Float %7.36%
Short Ratio8.23
AUPH Industry Overview
AUPH operates in the Biotechnology sub-industry within the Health Care sector. This group contains 18 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
26/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
11/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
70%
Outperformed 70% of sub-industries
3 Month Rank
42%
Outperformed 42% of sub-industries
6 Month Rank
35%
Outperformed 35% of sub-industries
Industry Fundamentals & Breadth
- Members
- 18
- New Highs
- 0%
- New Lows
- 11.1%
- Average ROE
- 3.7%
- Average Profit Margin
- 3.1%
- Average Operating Margin
- 1.6%
- Average P/E
- 63.0
- Average Fwd P/E
- 9.3
- Average Debt/Equity
- 0.1
AUPH Latest News, Press Relases and Analysis
7 hours ago - By: Chartmill
AUPH Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.64 | 373.774B | ||
| AMGN | AMGEN INC | 13.81 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.93 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.8 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.75 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.71 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.47 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.042B | ||
| INCY | INCYTE CORP | 10.54 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AUPH
Company Profile
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company is headquartered in Edmonton, Alberta. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Company Info
IPO: 2001-07-16
AURINIA PHARMACEUTICALS INC
#140, 14315 - 118 Avenue
Edmonton ALBERTA V8Z 7X8 CA
CEO: Peter Greenleaf
Employees: 128
Phone: 12507442487
AURINIA PHARMACEUTICALS INC / AUPH FAQ
Can you describe the business of AURINIA PHARMACEUTICALS INC?
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company is headquartered in Edmonton, Alberta. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
What is the stock price of AURINIA PHARMACEUTICALS INC today?
The current stock price of AUPH is 15.39 USD.
Does AURINIA PHARMACEUTICALS INC pay dividends?
AUPH does not pay a dividend.
What is the ChartMill rating of AURINIA PHARMACEUTICALS INC stock?
AUPH has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
When does AURINIA PHARMACEUTICALS INC (AUPH) report earnings?
AURINIA PHARMACEUTICALS INC (AUPH) will report earnings on 2026-07-29.
Can you provide the ownership details for AUPH stock?
You can find the ownership structure of AURINIA PHARMACEUTICALS INC (AUPH) on the Ownership tab.